Lynparza (Olaparib)
olaparib 100 mg tablet, 56 · ORAL · PBS code 12932P
AUTHORITY_REQUIREDWhat it costs
AU$3234.75 PBS-determined price per 112 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2022-04-01.
- • Repeats: 2.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Castration resistant metastatic carcinoma of the prostate
Initial treatment
The condition must be associated with a class 4 or 5 BRCA1 or BRCA2 gene mutation; AND
The treatment must not be subsidised in combination with: (i) chemotherapy, (ii) a novel hormonal drug; AND
The condition must have progressed following prior treatment that included a novel hormonal drug for this condition (metastatic/non-metastatic disease); AND
Patient must have a WHO performance status of 2 or less; AND
Patient must be undergoing treatment with this drug for the first time.
Sponsor: AstraZeneca Pty Ltd ABN 54 009 682 311
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.